Sarepta Therapeutics was awarded a voucher for a fast-track drug review by the Food and Drug Administration when the company's medicine for Duchenne muscular dystropy was approved Sept. 19. Now Sarepta is looking to sell the voucher to the highest bidder. Mick Wiggins/Ikon Images/Getty Images hide caption
A job reviewing drug applications at the Food and Drug Administration can be the springboard for a career in industry. Andrew Harnik/AP hide caption
A screenshot from a video touting a gap plan called "Premium Saver." Screenshot by NPR/Crema Design Studio hide caption
Cassie Ray (seen with her husband, Gerry) got a surprise bill from an out-of-network anesthesiologist after an operation. Courtesy of Cassie Ray hide caption
How big a deal is the spending on drugs for rare diseases? Mark Airs/Ikon Images/Getty Images hide caption
Mylan lobbied state legislatures for laws that require schools to stock EpiPens. Rich Pedroncelli/AP hide caption
Where are the generic alternatives to EpiPen and other expensive drugs that have lost patent protection? Victor J. Blue/Bloomberg via Getty Images hide caption
Mylan, the maker of EpiPen, says it will sell a generic version for $300 for a two-pack, a price that consumer advocates say is still too high. The device is used to treat severe allergic reactions. Daniel Acker/Bloomberg via Getty Images hide caption
Careful audits of a representative sampling of bills from 37 Medicare Advantage Programs in 2007 have revealed some consistent patterns in the way they overbill, a Center for Public Integrity investigation finds. Nick Shepherd/Ikon Images/Getty Images hide caption
The cost of an EpiPen two-pack has risen more than 400 percent in recent years. The drug is used to halt severe allergic reactions. Joe Raedle/Getty Images hide caption
This Lawson convenience store in Kowaguchi, Japan, sells a selection of prepared meals and fresh vegetables and meats, along with products aimed at the elderly. Many of the store's older customers find it hard to get to the supermarket, the store's manager says. Ina Jaffe/NPR hide caption
Mark Bertolini, CEO of Aetna, told the Justice Department in July that the insurer would walk away from many health exchanges if the government opposed the company's proposed deal for Humana. On Tuesday, Aetna followed through. Andrew Harrer/Bloomberg via Getty Images hide caption